Skip to main content
CDC Website

TB

Global Tuberculosis Report 2024

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

The 2024 edition of the report is, as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2024, 193 countries and areas with more than 99% of the world’s population and TB cases reported data.

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection.

2021 Hep B United & TB Elimination Alliance Summit

The 2021 Hep B United / TB Elimination Alliance Summit took place on November 2-3, 2021. This year’s theme was Centering Community to Advance Health Equity — inspired by the summit planning committee and the 2020 TB Summit design contest winner, Setie Asfaha of TB Free California. Scroll down to access resources from the summit.

TB Elimination Alliance Impact Report 2020-2021

Raise awareness about the link between LTBI and TB disease, address misperceptions, decrease stigma, and encourage and facilitate testing and treatment for LTBI and TB. Increase awareness of the recommended shorter treatment regimen for LTBI.
Create a culturally and linguistically appropriate LTBI and TB education, training and community engagement resources and activities that resonate with high priority AA and NH/PI communities. Encourage providers to test and treat LTBI among at-risk populations.